## Laurus Labs Limited Corporate Office

2<sup>nd</sup> Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 500034, Telangana, India T +91 40 6659 4333, 3980 4333, 2342 0500 / 501 F +91 40 6659 4320 / 3980 4320



December 09, 2021

To

The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal Street Mumbai – 400001

Code: 540222

То

The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051

Code: LAURUSLABS

Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited

Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated November 19, 2021

Dear Sirs,

This has reference to our disclosure dated November 19, 2021 regarding the signing of an investment agreement with M/s. Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire 26.62% stake (fully diluted basis), subject to completion of conditions precedent, for a cash consideration of approximately Rs. 46.00 Crores.

In this regard, we wish to update that the Company has paid the subscription amount of Rs.27.60 Crores (Rupees Twenty-Seven Crores and Sixty Lakhs only) as "Tranche 1 Subscription Amount" today (i.e. on December 09, 2021). Along with the Company, the senior management of the Company also paid the "Tranche 1 Subscription Amount" today.

This is for your information and record.

Yours faithfully,

For Laurus Labs Limited

G. Venkateswar Reddy Company Secretary

Registered Office: Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN: L24239AP2005PLC047518 T +91 891 660 1222, 306 1222, F +91 891 660 1270, 306 1270, E info@lauruslabs.com W lauruslabs.com





